Experts will convene at the third Miami Cancer Institute Summit of Americas on Immunotherapies for Hematologic Malignancies in January 2022 to discuss advances in immunologically and molecular based system therapies, new-targeted diagnostic and therapeutic strategies for lymphoma, myeloma, and leukemia, the role and timing of hematopoietic cell transplantation, and the latest on CAR T-cell therapies.
Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.
